TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8154506

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Furosemide (mean dose: 248 mg)
Number of subjects: 16
Study: 31826802

Group type: EXPERIMENTAL
Intervention: Paclitaxel micellar (250 mg/m2, 1-h infusion) + carboplatin (AUC 5-6)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Cr-EL paclitaxel (175 mg/m2, 3-h infusion) + carboplatin (AUC 5-6)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Paclitaxel micellar
Number of subjects: 789

Group type: COMPARATOR
Intervention: Cr-EL paclitaxel
Number of subjects: 789
Study: 30895326

Group type: EXPERIMENTAL
Intervention: Robot-assisted locomotor training for 60 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study: 29077818

Group type: EXPERIMENTAL
Intervention: RAPP (Recovery Assessment by Phone Points)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 997
Study: 25455873

Group type: EXPERIMENTAL
Intervention: Lidocaine (8.5-mL dose administered to the portio, cervix, and uterus)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 24064189

Group type: EXPERIMENTAL
Intervention: Negative writing condition (writing about a bad drinking experience)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Positive writing condition (writing about a good drinking experience)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Neutral writing condition (writing about the first day of college)
Number of subjects: 200
Study: 21876297

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment with continuous wave of 1.5w/cm² for 10 minutes before stretching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive stretching exercise
Number of subjects: 0
Study: 18535611

Group type: EXPERIMENTAL
Intervention: Coaxial phacoemulsification (CP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Biaxial phacoemulsification (MICS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study: 16802486

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (n=16)
Number of subjects: 48
Study: 12492743

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins A, C and E, selenium, methionine and ubiquinone) for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10688560

Group type: EXPERIMENTAL
Intervention: Open access follow up
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine booked appointments
Number of subjects: 180
Study: 9085313

Group type: EXPERIMENTAL
Intervention: Cefpodoxime 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefuroxime 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg
Number of subjects: 10
Study: 8105525

Group type: EXPERIMENTAL
Intervention: Ordinary least squares (OLS) estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transformed data using OLS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational study and clinical trial data
Number of subjects: 0
Study: 3545103

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31907026

Group type: EXPERIMENTAL
Intervention: 2-hydroxybenzylamine acetate (500 or 750 mg) administered every eight hours for two weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-hydroxybenzylamine acetate (500 or 750 mg)
Number of subjects: 0
Study: 29885994

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg intravenously every 2 weeks for 4 cycles)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone 500 mg/day intravenously for 3 days, then tapered, followed by 10 mg/day oral prednisone for 2 months)
Number of subjects: 112
Study: 26420905

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) focused on cognitive functioning
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham control interview focused on assessment and feedback about preferred learning styles
Number of subjects: 64
Study: 24131197

Group type: EXPERIMENTAL
Intervention: Chlorhexidine application
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 140
Study: 23106916

Group type: EXPERIMENTAL
Intervention: Motivational Care Planning (MCP)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 154
Study: 20390619

Group type: EXPERIMENTAL
Intervention: Starved (sitcom depicting individuals with eating disorders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: The Comeback (sitcom unrelated to eating disorders)
Number of subjects: 0
Study: 18524413

Group type: EXPERIMENTAL
Intervention: Pre-lunch condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Post-lunch condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dichotic Listening Task (DLT)
Number of subjects: 30
Study: 16243240

Group type: EXPERIMENTAL
Intervention: NSAID administered 1 hour postoperatively
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NSAID administered 1 hour preoperatively
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No scheduled administration pre- or postsurgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups (preemptive, posttreatment, no-treatment)
Number of subjects: 80
Study: 12363161

Group type: EXPERIMENTAL
Intervention: Winnie technique
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Transarterial technique
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined technique
Number of subjects: 69
Study: 10201663

Group type: EXPERIMENTAL
Intervention: Adenosine (25 microg x kg(‐1) x min(‐1))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remifentanil (0.02 microg x kg(‐1) x min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 32
Study: 7598681

Group type: EXPERIMENTAL
Intervention: Worrying about a stressor for a period of 4 minutes after exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging about the stressor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worrying about usual concerns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Settle-down control condition
Number of subjects: 0
Study: 2185965

Group type: EXPERIMENTAL
Intervention: 2% fenticonazole spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% cyclopyroxolamine spray
Number of subjects: 100
Study: 392622

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ergometrin
Number of subjects: 140

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 140
Study: 30148437

Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous)
Number of subjects: 99

Group type: COMPARATOR
Intervention: TNFi (infliximab)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Abatacept (after switching from TNFi)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Abatacept (for ANA/anti-dsDNA autoantibody-positive patients)
Number of subjects: 99
Study: 29244743

Group type: EXPERIMENTAL
Intervention: 6 g of creatine nitrate (CNH)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3 g of creatine nitrate (CNL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 28
Study: 26617438

Group type: EXPERIMENTAL
Intervention: Xiao-Ai-Tong (XAT) 200 mL, bid, for 7 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of XAT and morphine (20 mg and 30 mg, respectively)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XAT treatment
Number of subjects: 0
Study: 25096178

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 10

Group type: COMPARATOR
Intervention: MOD
Number of subjects: 10
Study: 22531635

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen or letrozole or a sequence of the two (5 years)
Number of subjects: 100
Study: 19193708

Group type: EXPERIMENTAL
Intervention: Silanated RC surfaces
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-silanated RC surfaces
Number of subjects: 60
Study: 18214123

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for eight weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg daily for eight weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15259325

Group type: EXPERIMENTAL
Intervention: Combination of standard training for spatial scanning and optokinetic stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard treatment for spatial scanning
Number of subjects: 2
Study: 10929897

Group type: EXPERIMENTAL
Intervention: In-office test detecting IgG antibodies to H. pylori (FlexPack HP, Abbott Diagnostics)
Number of subjects: 183

Group type: COMPARATOR
Intervention: IgG serum antibodies
Number of subjects: 183

Group type: COMPARATOR
Intervention: IgA antibodies
Number of subjects: 183

Group type: COMPARATOR
Intervention: Whole-blood test
Number of subjects: 183
Study: 9306027

Group type: EXPERIMENTAL
Intervention: Durex Ramses lubricated condoms
Number of subjects: 4637
Study: 7687079

Group type: EXPERIMENTAL
Intervention: Balloon dilatation of the prostate (BDP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 51
Study: 3470899

Group type: EXPERIMENTAL
Intervention: Combination of hexetidine and zinc ions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hexetidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zinc ions
Number of subjects: 10
Study: 31355924

Group type: EXPERIMENTAL
Intervention: Automated telephone call
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Personal call
Number of subjects: 620

Group type: COMPARATOR
Intervention: No follow-up call
Number of subjects: 620
Study: 27405512

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) program offered yearly from age 2 to 10.
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) program
Number of subjects: 731
Study: 26932169

Group type: EXPERIMENTAL
Intervention: SLIT plus vitamin D supplementation (1000 IU daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: SLIT plus placebo
Number of subjects: 50
Study: 24586591

Group type: EXPERIMENTAL
Intervention: Patient chart review training
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 123
Study: 22868933

Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention for tics
Number of subjects: 122

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 122
Study: 20969659

Group type: EXPERIMENTAL
Intervention: 2.5% polyacrylamide hydrogel
Number of subjects: 315

Group type: COMPARATOR
Intervention: nonanimal stabilized hyaluronic acid (NASHA)
Number of subjects: 315
Study: 17653846

Group type: EXPERIMENTAL
Intervention: Combined urinary and recombinant FSH (uFSH followed by rFSH)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 119
Study: 15682300

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12237477

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 episodes of 1 min ischemia
Number of subjects: 0
Study: 10424181

Group type: EXPERIMENTAL
Intervention: One-person transferring techniques
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Single hook method for repositioning
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Two-person draw sheet repositioning technique
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: General patient handling tasks
Number of subjects: 17
Study: 7493303

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 321
Study: 1968912

Group type: EXPERIMENTAL
Intervention: Propranolol LA (160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metoprolol CR/ZOK (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 437431

Group type: EXPERIMENTAL
Intervention: β-sitosterol (250 mg/kg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: chenic acid (10 mg/kg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: β-sitosterol + chenic acid
Number of subjects: 7
Study: 30517043

Group type: EXPERIMENTAL
Intervention: Selective tibialis posterior strengthening and iliopsoas stretching
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional exercise (towel curl exercises only)
Number of subjects: 28
Study: 27883237

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (1200 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Oral iron (mean daily dose of 70.5 mg)
Number of subjects: 65
Study: 25572026

Group type: EXPERIMENTAL
Intervention: TiNO stents
Number of subjects: 302

Group type: COMPARATOR
Intervention: E-ZES
Number of subjects: 302
Study: 23493575

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 22
Study: 21437754

Group type: EXPERIMENTAL
Intervention: Mechanical feedback device
Number of subjects: 81

Group type: COMPARATOR
Intervention: Classic ECC without the device
Number of subjects: 81
Study: 19679266

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 17374038

Group type: EXPERIMENTAL
Intervention: Naltrexone + Cognitive Behavioral Therapy (CBT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Naltrexone + Motivational Enhancement Therapy (MET)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo + MET
Number of subjects: 137
Study: 15353385

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day (12 mg bid)
Number of subjects: 699
Study: 11517441

Group type: EXPERIMENTAL
Intervention: Stavudine and didanosine (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine (group 2)
Number of subjects: 42
Study: 9664749

Group type: EXPERIMENTAL
Intervention: Avitriptan 75 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Avitriptan 150 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Avitriptan 200 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8143828

Group type: EXPERIMENTAL
Intervention: ECSC prediction equations for spirometric indices
Number of subjects: 100
Study: 30368884

Group type: EXPERIMENTAL
Intervention: EMT regulators expression in WI-FTC, PDTC, and ATC
Number of subjects: 62

Group type: COMPARATOR
Intervention: EMT regulators expression in FA and MI-FTC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Loss of E-CAD and EMT regulators expression
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EMT regulators expression
Number of subjects: 62
Study: 30124488

Group type: EXPERIMENTAL
Intervention: Patient blood management program
Number of subjects: 1000
Study: 26272237

Group type: EXPERIMENTAL
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy (RARC)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Cystectomy (LRC)
Number of subjects: 93
Study: 24493829

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BCL2L11 high expression
Number of subjects: 95
Study: 22760584

Group type: EXPERIMENTAL
Intervention: High-frequency tone presented in synchrony with the target display among low-tone distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Louder tone presented amongst quieter tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quieter tone presented amongst louder tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of a tone in an otherwise identical tone sequence
Number of subjects: 0
Study: 20546262

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 442
Study: 17397703

Group type: EXPERIMENTAL
Intervention: Imagine-patient perspective-taking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral perspective-taking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagine-self perspective-taking
Number of subjects: 0
Study: 17549950

Group type: EXPERIMENTAL
Intervention: Trunk Stability (TS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Leg Strength (LS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Trunk Stability and Leg Strength (TL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 55
Study: 15286240

Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis for HIV-exposed infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring for early determination of HIV-1 infection status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis for Pneumocystis pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling to parents or caregivers
Number of subjects: 0
Study: 10743871

Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 0
Study: 8630203

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone sodium phosphate (1 mg/kg up to 16 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1600972

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3879176

Group type: EXPERIMENTAL
Intervention: suprofen suppositories (alpha‐methyl‐4‐(2‐thienylcarbonyl)‐phenyl acetic acid)
Number of subjects: 90
Study: 31735613

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) filler injection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Polylactic Acid (PLA) filler injection
Number of subjects: 74
Study: 30530189

Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (ESG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study: 28831752

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.5 mg once daily for 8 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atrasentan 1.25 mg once daily for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25281755

Group type: EXPERIMENTAL
Intervention: TCN‐032
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22973945

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention including weekly nutrition and exercise education, exercise sessions, and nurse support (n = 51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group received a 12-week healthy lifestyle booklet (n = 50)
Number of subjects: 101
Study: 21301811

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 10 IU
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 20 IU
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19645964

Group type: EXPERIMENTAL
Intervention: REMD (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 35
Study: 17106665

Group type: EXPERIMENTAL
Intervention: Disc prosthesis
Number of subjects: 25

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (Disc prosthesis and ACDF)
Number of subjects: 25
Study: 14731173

Group type: EXPERIMENTAL
Intervention: Hollow screw (HS) implants
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hollow cylinder (HC) implants
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Angulated hollow cylinder (AHC) implants
Number of subjects: 89
Study: 11718071

Group type: EXPERIMENTAL
Intervention: Erythromycin intervention group
Number of subjects: 488

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 488
Study: 9208074

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.3 mg.kg‐1 with intravenous midazolam 2 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ketamine and midazolam)
Number of subjects: 40
Study: 8355505

Group type: COMPARATOR
Intervention: Very low-dose cytosine arabinoside (VLD-AC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-dose aclarubicin (LC-ACR)
Number of subjects: 39
Study: 3325317

Group type: EXPERIMENTAL
Intervention: split‐virion influenza vaccine (MFV‐Ject, Institut Merieux)
Number of subjects: 19

Group type: COMPARATOR
Intervention: sub‐unit vaccine (Fluvirin, Evans)
Number of subjects: 19
Study: 31629915

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 243

Group type: COMPARATOR
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four cycles followed by nivolumab 3 mg/kg every 2 weeks
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 243

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab
Number of subjects: 243
Study: 29751360

Group type: EXPERIMENTAL
Intervention: Intra-operative fluorescence angiography (IFA)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Standard care (surgery with no IFA)
Number of subjects: 880
Study: 26862693

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 61

Group type: COMPARATOR
Intervention: K3 rotary system
Number of subjects: 61
Study: 25139589

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1800-2400 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 97
Study: 22917575

Group type: EXPERIMENTAL
Intervention: Pre‐emptive valganciclovir therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis
Number of subjects: 70